醋酸甲地孕酮联合最佳支持疗法治疗晚期肿瘤伴营养不足患者的疗效及安全性

Efficacy and safety of megestrol acetate combined with optimal supporting treatment for malnutrition patients with advanced malignant tumor

目的探讨醋酸甲地孕酮联合最佳支持疗法治疗晚期恶性肿瘤伴营养不足的临床疗效及安全性。方法晚期恶性肿瘤伴营养不足患者86例,随机分为治疗组及对照组,每组43例,分别接受最佳支持治疗联合醋酸甲地孕酮、最佳支持治疗,比较治疗后6周及12周体重、进食量及Karnofsky评分的变化情况,观察治疗组不良反应发生情况。结果用药6周及12周后,治疗组体重改变有效率均高于对照组(P<0.05);用药6周后,两组进食量改变及Karnofsky评分有效率比较,差异无统计学意义(P>0.05),但用药12周后,治疗组进食量改变及Karnofsky评分的有效率均高于对照组(P<0.05)。治疗组无严重不良事件发生。结论醋酸甲地孕酮联合最佳支持治疗对改善恶性肿瘤患者的营养状况有明确疗效。

Objective To investigate the clinical efficacy and safety of megestrol acetate combined with the optimal supporting treatment for malnutrition patients with advanced malignant cancer. Methods A total of 86 patients with advanced maligant tumor complicated with malnutrition were randomly divided into treatment group （n = 43） and control group （n = 43）. The patients in the treatment group and control group were treated with megestrol acetate combined with the optimal supporting treatment and the optimal supporting treatment alone respectively. The variations of weight,food intake and Kamofsky score were compared between two groups 6 and 12 weeks after treatment. And the adverse reactions were observed in the treatment group. Results The effective rates of weight variation in the treatment group were all higher than those in the control group 6 and 12 weeks after treatment （P 〈0.05）. There were no significant differences in the effective ratess of food intake and Kamofsky score between two groups 6 weeks after treatment （P 〉 0. 05 ）, but the effective rates of food intake and Karnofsky＇s score in the treatment group were higher than those in the control group （ P 〈 0. 05 ）. No severe adverse reactions occurred in the treatment group. Conclusion Megestrol acetate combined with the optimal supporting treatment is effective for improving the nutritional status of patients with advanced malignant tumor.